Given that both IL-1α and IL-1β are expressed in COPD and during episodes of acute exacerbation[12], therapies targeted at the receptor rather than the individual ligands may be more relevant for limiting inflammation and exacerbations in COPD. This evidence concerns the gene IL1B and chronic obstructive pulmonary disease.